- Trials with a EudraCT protocol (59)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
59 result(s) found for: Chromosome 22.
Displaying page 1 of 3.
EudraCT Number: 2007-000208-34 | Sponsor Protocol Number: CAMN107A2303 | Start Date*: 2007-06-11 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chr... | ||||||||||||||||||
Medical condition: Adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) CZ (Completed) BE (Completed) IT (Completed) ES (Completed) SK (Completed) AT (Completed) FR (Completed) NL (Completed) FI (Completed) DK (Completed) DE (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017775-19 | Sponsor Protocol Number: CAMN107EIC01 | Start Date*: 2010-05-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase | |||||||||||||
Medical condition: Newly diagnosed Philadelphia chromosome and/or BCR-ABL positive chronic myeloid leukaemia (CML) in chronic phase in adult patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) BE (Completed) HU (Completed) ES (Completed) FI (Completed) GB (Completed) PT (Completed) DE (Completed) SE (Completed) CZ (Completed) DK (Completed) SK (Completed) GR (Completed) AT (Completed) LT (Completed) IT (Completed) LV (Completed) SI (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005712-27 | Sponsor Protocol Number: CA180056 | Start Date*: 2007-08-01 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chrom... | |||||||||||||
Medical condition: Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) GR (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) HU (Completed) ES (Completed) IT (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004230-40 | Sponsor Protocol Number: B1871006 | Start Date*: 2006-02-17 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc., a wholly owned subsidary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA | |||||||||||||
Full Title: A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias | |||||||||||||
Medical condition: Philadelphia Chromosome positive leukemias occur as a result of a reciprocal translocation between chromosomes 9 and 22. Its most common phenotype is Chronic Myelogenous Leukemia (CML), which has ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) HU (Completed) AT (Completed) FI (Completed) SE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022854-18 | Sponsor Protocol Number: GMALL-PH-01 | Start Date*: 2011-02-23 |
Sponsor Name:Dekan des Fachbereichs Medizin der Goethe Universität, represented by the Coordinating Investigator | ||
Full Title: OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIV... | ||
Medical condition: Philadelphia chromosome positive Acute Lymphoblastic Leukemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-006978-20 | Sponsor Protocol Number: HBS407 | Start Date*: 2007-11-21 | |||||||||||
Sponsor Name:Talon Therapeutics , Inc. | |||||||||||||
Full Title: A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic... | |||||||||||||
Medical condition: Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001622-24 | Sponsor Protocol Number: Spirit Version 12 | Start Date*: Information not available in EudraCT |
Sponsor Name:Newcastle Hospital Trust | ||
Full Title: Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic... | ||
Medical condition: Chronic Myeloid Leukaemia (Chronic Phase) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001754-18 | Sponsor Protocol Number: CLR_15_03 | Start Date*: 2017-06-07 | |||||||||||||||||||||
Sponsor Name:Sun Pharma Advanced Research Company Ltd. | |||||||||||||||||||||||
Full Title: A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myel... | |||||||||||||||||||||||
Medical condition: Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Prematurely Ended) ES (Ongoing) HU (Temporarily Halted) RO (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022855-46 | Sponsor Protocol Number: EWALL-PH-02 | Start Date*: 2011-07-13 |
Sponsor Name:Dekan des Fachbereichs Medizin der Goethe Universität, represented by the Coordinating Investigator | ||
Full Title: AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH NILOTINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHIL... | ||
Medical condition: Philadelphia chromosome positive Acute Lymphoblastic Leukemia in elderly Patients (55 years and older) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Prematurely Ended) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004551-30 | Sponsor Protocol Number: ICORG08-02Nilotinib | Start Date*: 2008-10-31 | |||||||||||
Sponsor Name:ICORG | |||||||||||||
Full Title: A phase II multi-center, open-label, study of Nilotinib at a dose of 300mg twice daily in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in ... | |||||||||||||
Medical condition: Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000678-27 | Sponsor Protocol Number: CABL001J12301 | Start Date*: 2021-08-10 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leuk... | |||||||||||||
Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) HU (Ongoing) DE (Ongoing) CZ (Ongoing) IT (Ongoing) ES (Ongoing) SK (Trial now transitioned) SE (Trial now transitioned) AT (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) BG (Ongoing) FI (Trial now transitioned) NL (Ongoing) DK (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000383-18 | Sponsor Protocol Number: LAL1913 | Start Date*: 2014-05-20 |
Sponsor Name:G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
Full Title: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented... | ||
Medical condition: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011675-79 | Sponsor Protocol Number: ACTIM | Start Date*: 2009-07-10 |
Sponsor Name:CH-Versailles | ||
Full Title: A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS®) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC®) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR... | ||
Medical condition: chronic phase chronic myelogenous leukaemia (CP-CML) patients in major molecular response. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001617-12 | Sponsor Protocol Number: AP24534-14-203 | Start Date*: 2017-10-09 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses | |||||||||||||
Medical condition: Chronic Phase Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) DE (Completed) FI (Prematurely Ended) ES (Ongoing) DK (Completed) NO (Ongoing) BE (Completed) FR (Ongoing) NL (Ongoing) PT (Completed) PL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001318-92 | Sponsor Protocol Number: AP24534-15-303 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib | |||||||||||||
Medical condition: Chronic Phase Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) DK (Prematurely Ended) CZ (Completed) PT (Completed) FR (Completed) AT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022638-96 | Sponsor Protocol Number: CAFQ056B2214 | Start Date*: 2011-06-15 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) FR (Ongoing) DK (Completed) DE (Completed) ES (Completed) Outside EU/EEA IT (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006185-15 | Sponsor Protocol Number: SPIRIT 2 | Start Date*: 2008-04-22 | |||||||||||
Sponsor Name:Newcastle-upon-Tyne Hospitals NHS Trust | |||||||||||||
Full Title: STI571 Prospective International RandomIsed Trial 2 - A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in pati... | |||||||||||||
Medical condition: newly-diagnosed chronic-phase Chronic myeloid leukaemia (CML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001169-32 | Sponsor Protocol Number: CA180-035 | Start Date*: 2005-11-16 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Acce... | ||
Medical condition: Subjects with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) or in Myeloid (My) or Lymphoid (Ly) Blast Phase (BP) or with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) HU (Completed) DK (Completed) IE (Completed) CZ (Completed) FI (Completed) ES (Completed) IT (Completed) BE (Completed) DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000657-29 | Sponsor Protocol Number: CSTI571K2301 | Start Date*: 2005-07-12 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP)... | |||||||||||||
Medical condition: Newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) ES (Completed) IT (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006854-17 | Sponsor Protocol Number: OPTIMDASATINIB 10/2008 | Start Date*: 2009-03-03 |
Sponsor Name:CH-Versailles | ||
Full Title: A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKA... | ||
Medical condition: Chronic phase chronic myelogenous leukaemia (CP-CML). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.